Literature DB >> 10767332

Characterization of the sialidase molecular defects in sialidosis patients suggests the structural organization of the lysosomal multienzyme complex.

K E Lukong1, M A Elsliger, Y Chang, C Richard, G Thomas, W Carey, A Tylki-Szymanska, B Czartoryska, T Buchholz, G R Criado, S Palmeri, A V Pshezhetsky.   

Abstract

Sialidosis is an autosomal recessive disease caused by the genetic deficiency of lysosomal sialidase, which catalyzes the hydrolysis of sialoglycoconjugates. The disease is associated with progressive impaired vision, macular cherry-red spots and myoclonus (sialidosis type I) or with skeletal dysplasia, Hurler-like phenotype, dysostosis multiplex, mental retardation and hepatosplenomegaly (sialidosis type II). We have analyzed the genomic DNA from nine sialidosis patients of multiple ethnic origin in order to find mutations responsible for the enzyme deficiency. The activity of the identified variants was studied by transgenic expression. One patient had a frameshift mutation (G623delG deletion), which introduced a stop codon, truncating 113 amino acids. All others had missense mutations: G679G-->A (Gly227Arg), C893C-->T (Ala298Val), G203G-->T (Gly68Val), A544A-->G (Ser182Gly) C808C-->T (Leu270Phe) and G982G-->A (Gly328Ser). We have modeled the three-dimensional structure of sialidase based on the atomic coordinates of the homologous bacterial sialidases, located the positions of mutations and estimated their potential effect. This analysis showed that five mutations are clustered in one region on the surface of the sialidase molecule. These mutations dramatically reduce the enzyme activity and cause a rapid intralysosomal degradation of the expressed protein. We hypothesize that this region may be involved in the interface of sialidase binding with lysosomal cathepsin A and/or beta-galactosidase in their high-molecular-weight complex required for the expression of sialidase activity in the lysosome.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10767332     DOI: 10.1093/hmg/9.7.1075

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  22 in total

Review 1.  Type II sialidosis: review of the clinical spectrum and identification of a new splicing defect with chitotriosidase assessment in two patients.

Authors:  A Caciotti; M Di Rocco; M Filocamo; S Grossi; F Traverso; A d'Azzo; C Cavicchi; A Messeri; R Guerrini; E Zammarchi; M A Donati; Amelia Morrone
Journal:  J Neurol       Date:  2009-07-01       Impact factor: 4.849

2.  A recurrent de novo mutation in KCNC1 causes progressive myoclonus epilepsy.

Authors:  Mikko Muona; Samuel F Berkovic; Leanne M Dibbens; Karen L Oliver; Snezana Maljevic; Marta A Bayly; Tarja Joensuu; Laura Canafoglia; Silvana Franceschetti; Roberto Michelucci; Salla Markkinen; Sarah E Heron; Michael S Hildebrand; Eva Andermann; Frederick Andermann; Antonio Gambardella; Paolo Tinuper; Laura Licchetta; Ingrid E Scheffer; Chiara Criscuolo; Alessandro Filla; Edoardo Ferlazzo; Jamil Ahmad; Adeel Ahmad; Betul Baykan; Edith Said; Meral Topcu; Patrizia Riguzzi; Mary D King; Cigdem Ozkara; Danielle M Andrade; Bernt A Engelsen; Arielle Crespel; Matthias Lindenau; Ebba Lohmann; Veronica Saletti; João Massano; Michael Privitera; Alberto J Espay; Birgit Kauffmann; Michael Duchowny; Rikke S Møller; Rachel Straussberg; Zaid Afawi; Bruria Ben-Zeev; Kaitlin E Samocha; Mark J Daly; Steven Petrou; Holger Lerche; Aarno Palotie; Anna-Elina Lehesjoki
Journal:  Nat Genet       Date:  2014-11-17       Impact factor: 38.330

3.  Thymoquinone from nutraceutical black cumin oil activates Neu4 sialidase in live macrophage, dendritic, and normal and type I sialidosis human fibroblast cells via GPCR Galphai proteins and matrix metalloproteinase-9.

Authors:  Trisha M Finlay; Preethi Jayanth; Schammim Ray Amith; Alanna Gilmour; Christina Guzzo; Katrina Gee; Rudi Beyaert; Myron R Szewczuk
Journal:  Glycoconj J       Date:  2010-03-06       Impact factor: 2.916

4.  Pitfalls in Diagnosing Neuraminidase Deficiency: Psychosomatics and Normal Sialic Acid Excretion.

Authors:  Imre F Schene; Viera Kalinina Ayuso; Monique de Sain-van der Velden; Koen L I van Gassen; Inge Cuppen; Peter M van Hasselt; Gepke Visser
Journal:  JIMD Rep       Date:  2015-07-05

5.  Clinical and genetic characteristics of type I sialidosis patients in mainland China.

Authors:  Rui-Juan Lv; Tao-Ran Li; Yu-Di Zhang; Xiao-Qiu Shao; Qun Wang; Li-Ri Jin
Journal:  Ann Clin Transl Neurol       Date:  2020-05-29       Impact factor: 4.511

Review 6.  Recent development in mammalian sialidase molecular biology.

Authors:  Eugenio Monti; Augusto Preti; Bruno Venerando; Giuseppe Borsani
Journal:  Neurochem Res       Date:  2002-08       Impact factor: 3.996

7.  Neu1 sialidase and matrix metalloproteinase-9 cross-talk is essential for Toll-like receptor activation and cellular signaling.

Authors:  Samar Abdulkhalek; Schammim Ray Amith; Susan L Franchuk; Preethi Jayanth; Merry Guo; Trisha Finlay; Alanna Gilmour; Christina Guzzo; Katrina Gee; Rudi Beyaert; Myron R Szewczuk
Journal:  J Biol Chem       Date:  2011-08-26       Impact factor: 5.157

8.  NEU1 sialidase regulates the sialylation state of CD31 and disrupts CD31-driven capillary-like tube formation in human lung microvascular endothelia.

Authors:  Chunsik Lee; Anguo Liu; Alba Miranda-Ribera; Sang Won Hyun; Erik P Lillehoj; Alan S Cross; Antonino Passaniti; P Richard Grimm; Bo-Young Kim; Paul A Welling; Joseph A Madri; Horace M DeLisser; Simeon E Goldblum
Journal:  J Biol Chem       Date:  2014-02-18       Impact factor: 5.157

9.  Dependence of pathogen molecule-induced toll-like receptor activation and cell function on Neu1 sialidase.

Authors:  Schammim Ray Amith; Preethi Jayanth; Susan Franchuk; Sarah Siddiqui; Volkan Seyrantepe; Katrina Gee; Sameh Basta; Rudi Beyaert; Alexey V Pshezhetsky; Myron R Szewczuk
Journal:  Glycoconj J       Date:  2009-12       Impact factor: 2.916

10.  Neuraminidase-1, a subunit of the cell surface elastin receptor, desialylates and functionally inactivates adjacent receptors interacting with the mitogenic growth factors PDGF-BB and IGF-2.

Authors:  Aleksander Hinek; Tetyana D Bodnaruk; Severa Bunda; Yanting Wang; Kela Liu
Journal:  Am J Pathol       Date:  2008-09-04       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.